Parametrica Management LTD Alnylam Pharmaceuticals, Inc. Transaction History

Parametrica Management LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	SELL	$170.77 - $211.65 $1.2 Million - $1.49 Million	-7,025 Reduced 68.56%	3,221 $570,000
Q2 2023 Aug 02, 2023	BUY	$185.01 - $212.05 $794,247 - $910,330	4,293 Added 72.11%	10,246 $1.95 Million
Q1 2023 May 09, 2023	SELL	$182.66 - $235.53 $647,895 - $835,424	-3,547 Reduced 37.34%	5,953 $1.19 Million
Q4 2022 Feb 07, 2023	SELL	$185.53 - $241.31 $805,014 - $1.05 Million	-4,339 Reduced 31.35%	9,500 $2.26 Million
Q3 2022 Nov 02, 2022	BUY	$138.54 - $232.0 $1.92 Million - $3.21 Million	13,839 New	13,839 $2.77 Million
Q4 2018 Feb 12, 2019	SELL	$62.67 - $88.33 $234,385 - $330,354	-3,740 Closed	0 $0
Q3 2018 Nov 06, 2018	BUY	$87.52 - $122.67 $327,324 - $458,785	3,740 New	3,740 $327,000
Q2 2018 Jul 23, 2018	SELL	$88.31 - $107.8 $523,501 - $639,038	-5,928 Closed	0 $0
Q1 2018 Apr 24, 2018	BUY	$115.92 - $148.54 $687,173 - $880,545	5,928 New	5,928 $706,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Parametrica Management LTD, based on Form 13F filings with the SEC.

Stay updated on Parametrica Management LTD with notifications on news.